Alnylam Pharmaceuticals (ALNY) PT Lowered to $125 at BMO Capital; Onpattro U.S. Approval Lacks Benefit From Cardiac Data

Alnylam Pharmaceuticals (ALNY) PT Lowered to $123 at Stifel

Stifel analyst Paul Matteis lowered the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $123.00 (from $125.00) while maintaining a Buy rating.

Matteis comments "As a follow up to our flash note reacting to the FDA approval of ALNY's patisiran, we are lowering... More

Alnylam Pharmaceuticals (ALNY) PT Lowered to $147 at Cowen on Strict Label

Cowen analyst Ritu Baral lowered the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $147.00 (from $157.00) while maintaining an Outperform rating after ONPATTRO received FDA Approval but the label is strictly for polyneuropathy.

"We are surprised by the lack of inclusion in the... More

Nomura Cuts Alnylam Pharma (ALNY) PT To $73 After ONPATTRO Gets Narrow Label

Nomura/Instinet analyst, Christopher Marai reiterated his Reduce rating on shares of Alnylam Pharmaceuticals (NASDAQ: ALNY) and cut his price target to $73 from $86 after the FDA approved ONPATTRO (patisiran) for adult hATTR with polyneuropathy (FAP), but not with cardiomyopathy (FAC). The narrower than expected label... More

UPDATE: Goldman Sachs Downgrades Alnylam Pharmaceuticals (ALNY) to Buy

(Updated - August 13, 2018 4:02 AM EDT)

(updated to add analyst comment)

Goldman Sachs analyst Terrance Flynn downgraded Alnylam Pharmaceuticals (NASDAQ: ALNY) from Conviction Buy to Buy with a price target of $155.00 (from $193.00).

Flynne believes the lack of cardio data in... More

Alnylam Pharmaceuticals (ALNY) PT Raised to $230 at B.Riley/FBR

B.Riley/FBR analyst Madhu Kumar raised the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $230.00 (from $210.00) while maintaining a Buy rating.

Kumar says the Onpattro US label does not impact the LT hATTR opportunity.

Alnylam Pharmaceuticals (ALNY) PT Lowered to $198 at JMP Securities

JMP Securities analyst Konstantinos Aprilakis lowered the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $198.00 (from $207.00) while maintaining a Market Outperform rating.

Alnylam Pharma (ALNY) to Resume Trading at 4:35 pm ET

Alnylam Pharma (NASDAQ: ALNY) to Resume Trading at 4:35 pm ET

Alnylam Pharma (ALNY) Says Annual List Price for Onpattro is $450,000; With Discounts $345,000 - Bloomberg, Citing Conf. Call

Alnylam Pharma (NASDAQ: ALNY) Says Annual List Price for Onpattro is $450,000; With Discounts $345,000 - Bloomberg, Citing Conf. Call

Alnylam Pharma (ALNY) Announces Alignment on Value-Based Agreements with Leading Health Insurers, Launches Comprehensive Patient Support Services for ONPATTRO

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it has agreed on the structure and key terms of value-based agreements (VBA) with leading health insurers for ONPATTRO (patisiran) lipid complex injection, a first-of-its-kind RNA interference (RNAi) therapeutic for the treatment of the polyneuropathy of hereditary transthyretin-mediated... More

Alnylam Pharma (ALNY) Confirms FDA Approval of ONPATTRO for Treatment of Polyneuropathy of hATTR Amyloidosis in Adults

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the United States Food and Drug Administration (FDA) approved ONPATTRO (patisiran) lipid complex injection, a first-of-its-kind RNA interference (RNAi) therapeutic, for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. ONPATTRO is the first and only FDA-approved treatment for this... More

Alnylam Pharma (ALNY) Patisiran (Onpattro) Approved by FDA

(Updated - August 10, 2018 1:00 PM EDT) (updated to add FDA release)

Alnylam Pharma (NASDAQ: ALNY) Patisiran (Onpattro) approved by FDA.

Below is a release from the FDA:

The U.S. Food and Drug Administration today approved Onpattro (patisiran) infusion for the treatment of peripheral nerve disease (polyneuropathy) caused by hereditary transthyretin-mediated amyloidosis (hATTR) in adult patients. This is the first FDA-approved treatment for patients with polyneuropathy caused by hATTR, a rare, debilitating and often fatal genetic disease characterized by the buildup of abnormal amyloid protein in... More